Press release
Lawsuit filed for Investors in shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)
A lawsuit was filed on behalf of investors in Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares.
Investors who purchased a shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) have certain options and for certain investors are short and strict deadlines running. Deadline: June 14, 2022. NASDAQ: AUPH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Canada based Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally.
On February 28, 2022, Aurinia Pharmaceuticals Inc. announced its financial results for the quarter and full year ended December 31, 2021. Among other items, Aurinia reported a year-over-year revenue decline and announced a lower-than-expected sales outlook for 2022.
Shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) declined from $33.97 per share on November 3, 2021, to as low as $9.91 per share on March 15, 2022.
The plaintiff claims that between May 7, 2021 and February 25, 2022, the Defendants made false and/or misleading statements and/or failed to disclose that Aurinia Pharmaceuticals Inc was experiencing declining revenues, that Aurinia Pharmaceuticals Inc's 2022 sales outlook for LUPKYNIS would fall well short of expectations, that accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects, that as a result, the Company had overstated its financial position and/or prospects for 2022, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors in shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) here
News-ID: 2607591 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for Aurinia
Investigation announced for Investors in shares of Aurinia Pharmaceuticals Inc. …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Aurinia Pharmaceuticals Inc..
Investors who are current long term investors in Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: AUPH stocks follows a lawsuit filed against Aurinia…
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Investor Notice: Deadline in Lawsuit …
A deadline is coming up on June 14, 2022 in the lawsuit filed for certain investors of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) over alleged securities laws violations by Aurinia Pharmaceuticals Inc.
Investors who purchased shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) have certain options and there are strict and short deadlines running. Deadline: June 14, 2022. NASDAQ: AUPH stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Investors in Aurinia Pharmaceuticals Inc. (NASDAQ: A …
Aurinia Pharmaceuticals Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Aurinia Pharmaceuticals Inc. regarding its business, its prospects and its operations were materially false…
Targeted Therapeutics Market Trends and Growth During 2021-2027 | Aurinia Pharma …
The Global Targeted Therapeutics market size is growing at a CAGR of 6.7% over the forecast period of 2021-2026.
Targeted therapy may be described as a treatment contemplated in the treatment of cancer. Targeted cancer therapy is also limited to molecularly targeted drugs/therapeutics. These treatments use precision drugs that identify and kill cancer cells in the body without affecting normal cells. Most targeted therapies do not resemble standard practices like chemotherapy…
Lupus Therapeutic Market Strategic Assessment by Key Players: Glaxosmithkline Pl …
Lupus Therapeutic Market report considers the latest upgrades while assessing the development of leading market players. This global market report is comprehensive and opens a door of worldwide market for the products. The report gives helpful insights which assist while launching a new product. This global market research report has complete overview of the market, covering various aspects such as product definition, segmentation based on various parameters, and the prevailing…
Lupus nephritis market 2020 Is Thriving Worldwide with F. Hoffmann-La Roche Ltd, …
Lupus nephritis market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned forecast period. Factors such as technological advancements, increasing awareness among people, increasing research grants and increasing government assistance are responsible for the growth of market lupus nephritis globally. The major players covered in lupus nephritis market are…
